PATL2 and Classical progressive supranuclear palsy: Various meta-analyses on human transcriptome studying aging, Alzheimer’s disease, as well as other neurodegenerative conditions (e.g., Huntington’s disease, progressive supranuclear palsy, amyotrophic lateral sclerosis), have not found a significant association between PATL2 expression levels and disease risk63–65.